Home › GLP-1 Medications › Wegovy (semaglutide)
Latest four-week snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.
GLP-1 Medications · 1 wave · n=72 answers, pooled
How often each assistant brings the brand up in recommendation answers.
| assistant | share of voice | answers |
|---|---|---|
| ChatGPT | 4% | 1 of 24 |
| Claude | 0% | 0 of 24 |
| Gemini | 8% | 2 of 24 |
Wave-by-wave share of recommendation answers that named this brand.
| wave | share of voice | answers | change |
|---|---|---|---|
| 2026-08-05 | 4% | 3 of 72 |
Recurring descriptions in the assistants' own words, grouped by theme.
“If you have established cardiovascular disease and that's a major concern, Wegovy has an edge — the SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease without diabetes”
“Wegovy is also FDA-approved to reduce the risk of major cardiovascular events (like heart attacks and strokes) in adults with obesity and established cardiovascular disease.”
“If you have established cardiovascular disease and that's a major concern, Wegovy has an edge — the SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease without diabetes”
“| You have established cardiovascular disease—e.”
“If you have established cardiovascular disease and that's a major concern, Wegovy has an edge — the SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease without diabetes”
“* **If Weight Loss is Your Only Goal:** While Trulicity does cause moderate weight loss (an average of **4 to 11 pounds** depending on the dose), it is *not* FDA-approved for weight loss.”
“* *Efficacy:* Highly effective, with clinical trials showing an average weight loss of around 15%.”
“newer GLP-1 medications—such as **Wegovy (semaglutide)** or **Zepbound (tirzepatide)**—are much more effective, often helping patients lose 15% to 20% of their body weight.”
“Wegovy is also FDA-approved to reduce the risk of major cardiovascular events (like heart attacks and strokes) in adults with obesity and established cardiovascular disease.”
“* *How it works:* A weekly injection that targets both GLP-1 and GIP receptors (a "dual agonist").”
5 exact quoted mentions in this snapshot, grouped by coded tone.
“**Wegovy (semaglutide)** | It has an FDA indication to reduce major cardiovascular events in qualifying adults”
“A weekly injection that targets GLP-1 receptors. *Efficacy:* Highly effective, with clinical trials showing an average weight loss of around 15%. It is also FDA-approved to reduce the risk of major cardiovascular events (like heart attacks ”
“Wegovy is also FDA-approved to reduce the risk of major cardiovascular events (like heart attacks and strokes) in adults with obesity and established cardiovascular disease.”
“newer GLP-1 medications—such as **Wegovy (semaglutide)** or **Zepbound (tirzepatide)**—are much more effective, often helping patients lose 15% to 20% of their body weight.”
“If you have established cardiovascular disease and that's a major concern, Wegovy has an edge — the SELECT trial showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascu”
2 of 5 mentions appear alongside an identifiable web citation. Citation does not establish causation.
| cited source | mentions |
|---|---|
| procarenow.com | 1 |
| justmelt.com | 1 |
| primetherapeutics.com | 1 |
Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.